1 Title: Does susceptibility to novel coronavirus (COVID-19) infection

2 differ by age?: Insights from mathematical modelling

3 Authors: Ryosuke Omori¹, Ryota Matsuyama², Yukihiko Nakata³

4 Affiliations:

- ⁵ ¹ Research Center for Zoonosis Control, Hokkaido University, Kita-ku, Sapporo-shi,
- 6 Hokkaido 001-0020, Japan
- 7 ² Graduate School of Biomedical and Health Sciences, Hiroshima University
- 8 ³ Department of Physics and Mathematics, Aoyama Gakuin University
- 9 (Correspondence to Ryosuke Omori at: Address: Kita-20 Nishi-10, Kita-Ku, Sapporo,
- 10 001-0020, Japan; Tel: +81-11-706-9488, Fax: +81-11-706-9491; Email:
- 11 omori@czc.hokudai.ac.jp)
- 12
- 13

14

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

15 Abstract

16	Among Italy, Spain, and Japan, the age distributions of novel coronavirus (COVID-19)
17	mortality show only small variation even though the number of deaths per country
18	shows large variation. To understand the determinant for this situation, we constructed a
19	mathematical model describing the transmission dynamics and natural history of
20	COVID-19 and analyzed the dataset of fatal cases of COVID-19 in Italy, Spain, and
21	Japan. We estimated the parameter which describes the age-dependency of
22	susceptibility by fitting the model to reported data, taking into account the effect of
23	change in contact patterns during the outbreak of COVID-19, and the fraction of
24	symptomatic COVID-19 infections. Our modelling study revealed that if the mortality
25	rate or the fraction of symptomatic infections among all COVID-19 cases does not
26	depend on age, then unrealistically different age-dependencies of susceptibilities against
27	COVID-19 infections between Italy, Japan, and Spain are required to explain the similar
28	age distribution of mortality but different basic reproduction numbers (R_0). Variation of
29	susceptibility by age itself cannot explain the robust age distribution in mortality by
30	COVID-19 in those three countries, however it does suggest that the age-dependencies
31	of i) the mortality rate and ii) the fraction of symptomatic infections among all COVID-
32	19 cases determine the age distribution of mortality by COVID-19.

33 Introduction

34	Since its emergence, coronavirus disease 2019 (COVID-19) has resulted in a
35	pandemic and has produced a huge number of cases worldwide (World Health
36	Organization, 2020). As of May 29, 2020, the number of confirmed cases in Italy was
37	231,139, with 237,141 in Spain, and 16,683 in Japan (World Health Organization,
38	2020). Of those infected, it has been reported that elderly individuals account for a large
39	portion of fatal cases inducing a large heterogeneity in the age distribution of mortality
40	(Dowd et al., 2020; Onder et al., 2020; Wu et al., 2020).
41	The expected value of mortality (the number of deaths, hereafter referred to as
42	mortality) is calculated as the product of the number of cases and the mortality rate
43	among cases (hereafter referred to as morality rate). As the background mechanism of
44	the heterogeneity of mortality by age, the association of two epidemiological factors
45	with mortality can be considered: i) the age-dependency of susceptibility to infection,
46	which is related to the heterogeneity in the number of cases, and ii) the age-dependency
47	of severity, which is related to the heterogeneity in the mortality rate, e.g. the rate of
48	becoming symptomatic, severe, or fatal case among infected individuals. For the first
49	factor, a high susceptibility for infection will generate a larger number of infections and
50	result in an increase in fatal cases. The possibility of heterogeneity in susceptibility by

51	age was pointed out by the analysis of epidemiological data reported from Wuhan,
52	China (Lee et al., 2020; Wu et al., 2020; Zhang et al., 2020) and from Iceland
53	(Gudbjartsson, 2020). For the second factor, an increase in severity will result in a
54	higher mortality rate and subsequently a rise in the number of fatal cases. This
55	assumption is also reasonable because elder age as well as the existence of
56	comorbidities, which are likely with aging, have been reported as risk factors for severe
57	COVID-19 infections (Bonanad et al., 2020; Guan et al., 2020; Liu et al., 2020; Shi et
58	al., 2020; Verity et al., 2020; Zhou et al., 2020). Although not yet shown in relation to
59	severe acute respiratory syndrome corona virus 2 (SARS Cov-2), which is the causal
60	agent of COVID-19, the presence of age-dependent enhancement of severity has been
61	suggested in SARS coronavirus by the analysis of the innate immune responses in the
62	BALB/c mouse model (Baas et al., 2008; Chen et al., 2010; Roberts et al., 2005).
63	Additionally, it has been suggested that antibody-dependent enhancement (ADE) can
64	contribute to the formation of the observed age-dependency of severity, as suggested in
65	SARS and Middle East respiratory syndrome (MERS) cases (Arabi et al., 2016; Drosten
66	et al., 2014; Tay et al., 2020; Tetro, 2020; Wan et al., 2018; Yang et al., 2005).
67	Interestingly, the age distribution of mortality by COVID-19 (the distribution of
68	the proportion of deaths per age group among all deaths), is similar between Italy,

69	Japan, and Spain, even though the number of deaths are quite different among them
70	(Ministry of Health, Labor and Welware, 2020; Epicentro, Istituto Superiore di Sanità,
71	2020; Centro de Coordinación de Alertas y Emergencias Sanitarias, 2020). The large
72	difference in the number of deaths between the countries suggests a large difference in
73	their basic reproduction numbers, R_0 s. An independency between age distribution of
74	mortality by COVID-19 and R_0 is suggested. From this independency of age
75	distributions of mortality from R_0 , it can be expected that the contribution of
76	heterogeneity in susceptibility by age to forming the age distribution of mortality is
77	small. That is because, as we will show in this paper, though the age-dependency of
78	severity will naturally produce a proportional effect on the distribution of mortality and
79	result in the formation of robust distributions, when the age-dependency of
80	susceptibility forms the age distribution of mortality, the age distribution of mortality
81	highly depends on R_0 and shows variability.
82	To understand the background of robust age distribution of mortality with varied
83	R_0 , we constructed a mathematical model describing the transmission dynamics of
84	COVID-19 and analyzed the impact of age-dependent susceptibility on the age
85	distribution of mortality. The heterogeneity in social contacts by age may also
86	contribute to the age distribution of mortality. Our model took into account the

87	heterogeneity in social contacts by age and country, and the effect of behavioral change
88	outside of the household during the outbreak. We also estimated and compared the age-
89	dependent susceptibility in Japan, Italy, and Spain to argue the existence of
90	heterogeneity in susceptibility among age groups.
91	

92 **Results**

93	Our result shows variation of susceptibility among age groups measured by the
94	exponent parameter φ can explain the age distribution of mortality by COVID-19
95	(figure 2(a)). However, the age distribution of mortality formed by the age-dependency
96	of susceptibility is influenced by the value of R_0 (figure 2(b)), which cannot explain the
97	similarity in age distributions of mortality among Italy, Japan, and Spain. On the other
98	hand, if susceptibility is constant among age groups, the impact of R_0 is quite small on
99	the age distribution of mortality (figure 3).
100	Assuming that the age-dependency of mortality by COVID-19 is determined by
101	only age-dependent susceptibility, i.e., the mortality rate does not depend on age, the
102	exponent parameter, φ , describing the variation of susceptibility among age groups for
103	each country, Italy, Japan, and Spain, was estimated as shown in figure 4. From the
104	difference of the R_0 value and country, the estimated value of φ is largely varied. The

105	impact of reductions in contacts outside of the household on the estimated value of φ
106	was small. The estimate of φ in Italy, assuming a range of $R_0 = 2.4-3.3$ (Zhuang et al.,
107	2020; D'Arienzo and Coniglio, 2020) was 15.0 (95% CI = 14.0-16.0), 16.3 (95% CI =
108	14.9-17.7), and 16.9 (95% CI = 15.4-18.4) for 80%, 40%, and no reduction in contacts
109	outside of the household. For Japan, the estimate of φ assuming $R_0 = 1.7$ (Expert
110	Meeting on the Novel Coronavirus Disease Control, 2020) was 4.2 (95%CI = 3.7-4.9),
111	5.5 (95%CI = 4.9-6.3), and 6.1 (95%CI = 5.4-6.9) for 80%, 40%, and no reduction in
112	contacts outside of the household. When it comes to Spain, the estimate of φ assuming
113	an $R_0 = 2.9$ (Caicedo-Ochoa et al., 2020) was 10.5 (95%CI = 10.4-10.6), 11.7 (95%CI =
114	11.6-11.9), and 12.3 (95%CI = 12.2-12.5) for 80%, 40%, and no reduction in contacts
115	outside of the household.
116	The estimates of φ , assuming that the fraction of infections becoming
117	symptomatic does not depend on age, were also varied by the value of R_0 and by
118	country (figure 5, 6 and 7). Employing the same assumptions of R_0 value, the estimate
119	of φ in Italy was 4.8 (95% CI = 4.2-5.3), 5.4 (95% CI = 4.9-5.9), and 5.7 (95% CI = 5.1-
120	6.2) for 80%, 40%, and no reduction in contacts outside of the household. For Japan, the
121	estimate of φ was 0.0 (95%CI = 0.0-0.9), 0.0 (95%CI = 0.0-1.1), and 0.0 (95%CI = 0.0-0.9)
122	1.2) for 80%, 40%, and no reduction in contacts outside of the household. For Spain, the

123 estimate of φ was 1.7 (95%CI = 1.4-1.9), 2.2 (95%CI = 1.9-2.5), and 2.5 (95%CI = 2.1-

124 2.8) for 80%, 40%, and no reduction in contacts outside of the household.

125

126 **Discussion**

127	In the present study, we explored the role of susceptibility to COVID-19 in
128	explaining the age distribution of mortality by COVID-19. Interestingly, the age
129	distributions of mortality from COVID-19 are quite similar between Italy, Japan, and
130	Spain (figure 1). When comparing the age distributions of mortality, only the
131	comparison between Italy and Spain is significant (p <0.05 in Wilcoxon rank sum test
132	with Bonferroni correction). On the other hand, the numbers of deaths are quite
133	different (29,525 for Italy, 400 for Japan, 18,818 for Spain). Indeed, R_0 values are
134	largely different: 2.4-3.3 for Italy (Zhuang et al., 2020; D'Arienzo and Coniglio, 2020),
135	1.7 for Japan (Expert Meeting on the Novel Coronavirus Disease Control, 2020), and
136	2.9 for Spain (Caicedo-Ochoa et al., 2020). If the variation of mortality by age is
137	determined by only the age-dependency of susceptibility, the age distribution of
138	mortality is affected by R_0 as shown in figure 2(b). However, we observed a similarity
139	in age distributions of mortalities between Italy, Japan, and Spain where their R_0 s are
140	quite different. Indeed, unrealistically different φ s among these three countries are

141 required to explain their age distribution of mortality for both settings, i) age-

142	independent mortality,	, and, ii)	the	fraction	of infections	that	becomes sy	mptomatic
-----	------------------------	------------	-----	----------	---------------	------	------------	-----------

- 143 among all COVID-19 cases, f_s , does not depend on age. Although we cannot fully reject
- 144 the existence of age-dependency in susceptibility, our results suggest that it does not
- 145 largely depend on age, but rather that age-dependency in severity highly contributes to
- 146 the formation of the observed age distribution in mortality.
- 147 The estimates of φ s assuming age independency in symptomatic infections were

smaller than those that assumed age independency in mortality. This suggests that the

- 149 age-dependency of the confirmed case fatality rate (cCFR), which can be biased by the
- 150 age-dependent difference of the fraction of symptomatic infections among all cases,
- 151 partially explains the age distribution in mortality. Indeed, when we assumed that the

152 fraction of symptomatic infections was not dependent on age, the estimate of φ in Japan

153 was close to zero in all scenarios regarding the fraction of symptomatic infections,

154 meaning that susceptibility is constant among age groups (figure 5). Although we

155 observed φ s around 5 in Italy and 2 in Spain, this does not mean straightforwardly that

156 susceptibility is age dependent because there is room for an alternative explanation: not

- 157 susceptibility, but an age-dependent fraction of symptomatic infections can explain this
- age-dependency. Unfortunately, as we do not yet have detailed data regarding the age-

159	dependent fraction of symptomatic infections and the rate of diagnosis in COVID-19,
160	we cannot conclude which factors (i.e., susceptibility or the fraction of symptomatic
161	infection among all cases) contributed to the observed age-dependency.
162	Wu et al. (2020) showed variation of susceptibility to symptomatic infection by
163	age. This susceptibility can be expressed as the product of the susceptibility and the
164	fraction of symptomatic infection among all cases. To accurately understand
165	susceptibility (i.e., without the constraint of the symptom onset), estimates of the age-
166	dependent fraction of symptomatic infections is required.
167	To understand the mechanism of age-dependency of mortality by COVID-19, an
168	accurate age-dependent mortality rate is required. To estimate the age-dependent
169	mortality rate, an accurate estimate of the case fatality rate is required. However, the
170	number of cases, which is the denominator of the case fatality rate, is difficult to
171	estimate for COVID-19 due to changes in the testing rate (Gostic et al., 2020a; Gostic et
172	al., 2020b; Omori et al. 2020), the change of case definition (Tsang et al. 2020),
173	selection biases (Bar-on et al., 2020), and the delay between the onset of symptoms and
174	death (Linton et al., 2020; Shim et al., 2020; Sun et al., 2020; Verity et al., 2020) as
175	were the cases we experienced in the surveillance of other emerging diseases (Ghani et
176	al., 2005; Garske et al., 2008). To address this problem, implementation of active

177 epidemiological surveillances, such as a large-scale cohort study including real-time178 detection of infections, should be considered.

- 179 From the modelling perspective on mortality by Covid-19, age-dependency of
- 180 severity should be carefully taken into consideration. In particular, in the mathematical
- 181 models of ADE, the previous models employed three types of assumptions (Woodall
- and Adams, 2014), the assumption of: increasing susceptibility to infection (Recker et
- al., 2009; Tang et al., 2018), increasing transmissibility once infection occurred
- 184 (Ferguson et al., 1999; Ferguson and Andreasen, 2002; Recker et al., 2009), and
- 185 increasing severity and/or mortality associated with infection (Kawaguchi et al., 2003).
- 186 Based on our results and from the biological/epidemiological observations of past
- 187 SARS and MERS cases, the "increasing severity" assumption should be taken into
- account when analyzing SARS Cov-2 epidemics.
- 189 In conclusion, the contribution of age-dependency to susceptibility is difficult to
- 190 use to explain the robust age distribution in mortalities by COVID-19, and it suggests
- 191 that the age-dependencies of the mortality rate and the fraction of symptomatic
- 192 infections among all COVID-19 cases determine the age distribution in mortality from
- 193 COVID-19. Further investigations regarding age-dependency on the fraction of

194	infections	becoming	symptomatic	is required t	o understand	the mechanism	behind the
-----	------------	----------	-------------	---------------	--------------	---------------	------------

- 195 mortality by COVID-19 infections.
- 196

197 Methods

- 198 **1. Data**
- 199 We analyzed the number of mortalities caused by COVID-19 in Italy reported
- 200 on 13th May 2020, Japan reported on 7th May 2020, and Spain reported on 12th May
- 201 2020. The data were collected from public data sources in each country (Ministry of
- 202 Health, Labor and Welware, 2020; Epicentro, Istituto Superiore di Sanità, 2020; Centro
- 203 de Coordinación de Alertas y Emergencias Sanitarias, 2020).

204

205 **2. Model**

To understand the background of robust age distribution of mortality with varied R_0 , we employed a mathematical model describing transmissions of COVID-19, an agestructured SEIR model, which can be written as;

209 $S'_{n} = -\beta \sigma_{n} S_{n} \left(\sum_{m} k_{n,m} I_{m} \right), \tag{1}$

210
$$E'_{n} = \beta \sigma_{n} S_{n} \left(\sum_{m} k_{n,m} I_{m} \right) - \varepsilon E_{n}, \qquad (2)$$

211
$$I'_{n} = \varepsilon E_{n} - (\gamma + \delta_{n})I_{n}, \qquad (3)$$

212
$$R'_{n} = \gamma I_{n}, \tag{4}$$

213
$$D'_n = \delta_n I_n, \tag{5}$$

214 where S_n , E_n , I_n , R_n and D_n represent the proportion of susceptible, latent, infectious,

recovered and dead among the entire population, and the subscript index *n* denotes age group. We stratified the entire population by into eight groups, n = 1, 2, 3, 4, 5, 6, 7, and

217 8 for < 10 years old (yo), 10-19 yo, 20-29 yo, 30-39 yo, 40-49 yo, 50-59 yo, 60-69 yo,

218 and 70+ yo. β , $k_{n,m}$, ε , γ and δ_n represent a transmission coefficient, an element of the

219 contact matrix between age group n and m, the progression rate from latent to

220 infectious, recovery rate and mortality rate among age group *n*, respectively. σ_n denotes

221 the susceptibility of age group n. For the sake of simplicity, births and deaths by other

than COVID-19 were ignored. To take into account the effect of behavioral changes

223 outside of the household during the outbreak, $k_{n,m}$ is decomposed by a matrix for

224 contacts within household $k_{in,n,m}$ and that for contacts outside the household $k_{out,n,m}$;

 $k_{n,m} = k_{in,n,m} + \alpha k_{out,n,m},\tag{6}$

where α denotes the reduced fraction of contacts outside of the household. We modelled age specific susceptibility as

228

225

$$\sigma_n = c n^{\varphi}.$$
 (7)

229 Where c is a constant among all age groups, φ denotes the exponent parameter

230 describing the variation of susceptibility among age groups. An increase in φ means an

231 increase in the variation of susceptibility among age groups, and $\varphi=0$ means that

232 susceptibility is equal among all age groups

233

234 **3.** Parameterizations

3; this version posted June 9, 2020. The copyright holder for this preprint medRxiv preprint doi: https://doi.org/10.1101/2 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

235	We parameterized ε and γ using the values from a previous modelling study of COVID
236	19 (Prem et al., 2020). We referred to the contact matrices for Italy, Japan, and Spain
237	from Prem et al. (Prem et al., 2017). β and c were controlled such that the basic
238	reproduction number, R_0 , becomes arbitral values. R_0 was calculated by constructing a
239	next generation matrix (Diekman and Heesterbeek, 2000; Mossong et al., 2008) using
240	each country's demographic data obtained from a public data source (United Nations,
241	2020).

242

243 4. Fitting

244 We calculated the proportions of deaths in the age group n among all deaths, d_n 245 $(= D_n(\infty) / \sum_n D_n(\infty))$, and fitted them to the observed data in each country. The 246 mortality rate among age group n, δ_n , is required to calculate d_n , however, a reliable 247 estimate of δ_n for COVID-19 is difficult to obtain. Due to the uncertainty of the fraction 248 of symptomatic infections per age group, δ_n is difficult to estimate from observed data, 249 i.e., the confirmed case fatality rate among age group n (cCFR_n). Since an estimate of δ_n 250 is difficult to obtain, we employed two different settings to calculate d_n , i) δ_n is assumed 251 to be a constant among all age groups, or, ii) δ_n is calculated from cCFR_n assuming that 252 the fraction of symptomatic infections among all COVID-19 cases (f_s) is not dependent 253 with age.

254 In setting i), the value of δ_n is not required to estimate d_n once the value of R_0 is 255 given. We calculated d_n by calculating the proportions of recovered persons per age group among all recovered persons $R_n(\infty)/\sum_n R_n(\infty)$ instead of $D_n(\infty)/\sum_n D_n(\infty)$. 256 257 In our model, shown in equation (1)-(4), $R_n(\infty)/\sum_n R_n(\infty)$ is determined by the value 258 of R_0 completely when all parameter values other than β and δ_n are fixed, and

259 $D_n(\infty)/\sum_n D_n(\infty) = R_n(\infty)/\sum_n R_n(\infty)$ if $\delta_n \neq 0$. The proof can be found in 260 supplementary file 1.

261 The assumption in setting i), δ_n is constant among all age groups, may be too 262 strong for the COVID-19 epidemic. To take into account the age-dependency of mortality by COVID-19, δ_n was calculated from the cCFR_n assuming that f_s is not 263 264 dependent with age. As for the setting ii), assuming three scenarios; $f_s = 0.05, 0.25$, and 265 0.5, δ_n for each country were calculated using cCFR_n in each country. We obtained δ_n 266 by solving cCFR_n = $\delta_n / [f_s(\delta_n + \gamma)]$. 267 We solved the model shown in equations (1)-(5) numerically, and d_n was 268 calculated after sufficient time was given to finish the epidemics. We estimated φ using 269 a log likelihood function describing the multinomial sampling process of deaths per age 270 group; $\sum_{n} D_n \log[d_n(\varphi)].$ 271 (8) 272 Maximum likelihood estimates of φ with given R_0 were obtained by maximizing

equation (8) and the profile likelihood-based confidence intervals were computed.

274

275 Acknowledgement

276 The authors gratefully acknowledge the manuscript language review of Dr Heidi L.

277 Gurung.

278 Competing interests

279 The authors declare no conflicts of interest.

280 Funding source

281	R.O. acknowledges	support from the	he Japan Societ	ty for the Pr	omotion of	Science (JSPS)
	0	1 1	1	-			

- 282 Grant-in-Aid for Young Scientists 19K20393. Y.N. was supported by JSPS Grant-in-
- Aid for Young Scientists (B) 16K20976. The funders had no role in study design, data
- 284 collection and analysis, decision to publish, or preparation of the manuscript.

285 Ethical approval

286 This study was based on publicly available data and did not require ethical approval.

287

288 **References**

- 289 1. World Health Organization. Coronavirus disease (COVID-2019) situation reports -
- 290 130. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-

291 2019/situation-reports. (Accessed 29th May 2020)

- 292 2. Dowd JB, Andriano L, Brazel DM, Rotondi V, Block P, Ding X, Liu Y, Mills MC.
- 293 Demographic science aids in understanding the spread and fatality rates of COVID-

294 19. Proc Natl Acad Sci. 2020; 117(18):9696-9698. doi:10.1073/pnas.2004911117.

- 295 3. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients
- 296 Dying in Relation to COVID-19 in Italy. JAMA. 2020;323:1775-1776.
- 297 doi:10.1001/jama.2020.4683
- 298 4. Wu JT, Leung K, Bushman M, Kishore N, Niehus R, de Salazar PM, Cowling BJ,
- 299 Lipsitch M, Leung GM. Estimating clinical severity of COVID-19 from the

300 transmission dynamics in Wuhan, China. Nat Med. 2020;26:506-510.

- 301 doi:10.1038/s41591-020-0822-7
- 302 5. Lee PI, Hu YL, Chen PY, Huang YC, Hsueh PR. Are children less susceptible to
- 303 COVID-19?. J Microbiol Immunol Infect. 2020;S1684-1182(20)30039-6.
- 304 doi:10.1016/j.jmii.2020.02.011
- 305 6. Zhang J, Dong X, Cao Y, Yuan Y, Yang Y, Yan Y, Akdis CA, Gao Y. Clinical
- 306 characteristics of 140 patients infected with SARS CoV 2 in Wuhan, China.
- 307 Allergy. 2020;0:1-12. doi:10.1111/all.14238
- 308 7. Gudbjartsson DF, Helgason A, Jonsson H, Magnusson OT, Melsted P, Norddahl
- 309 GL, Saemundsdottir J, Sigurdsson A, Sulem P, Agustsdottir AB, Eiriksdottir B,
- 310 Fridriksdottir R, Gardarsdottir EE, Georgsson G, Gretarsdottir OS, Gudmundsson
- 311 KR, Gunnarsdottir TR, Gylfason A, Holm H, Jensson BO, Jonasdottir A, Jonsson
- 312 F, Josefsdottir KS, Kristjansson T, Magnusdottir DN, le Roux L, Sigmundsdottir G,
- 313 Sveinbjornsson G, Sveinsdottir KE, Sveinsdottir M, Thorarensen EA,
- 314 Thorbjornsson B, Löve A, Masson G, Jonsdottir I, Möller AD, Gudnason T,
- 315 Kristinsson KG, Thorsteinsdottir U, Stefansson K. Spread of SARS-CoV-2 in the
- 316 Icelandic Population. N Engl J Med. 2020;NEJMoa2006100.
- 317 doi:10.1056/NEJMoa2006100.
- 8. Bonanad C, García-Blasabe S, Tarazona-Santabalbina F, Sanchis J, Bertomeu-
- 319 González V, Fácila L, Ariza A, Núñez J, Cordero A. The effect of age on mortality
- 320 in patients with Covid-19: a metanalysis with 611,583 subjects. J Am Med Dir
- 321 Assoc. 2020;In Press. doi:10.1016/j.jamda.2020.05.045
- 322 9. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui
- 323 DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY,
- 324 Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P,
- 325 Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong

|--|

- 327 of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720.
- 328 doi: 10.1056/NEJMoa2002032.
- 329 10. Liu k, Chen Y, Lin R, Han K., Clinical features of COVID-19 in elderly patients: A
- 330 comparison with young and middle-aged patients. J Infect. 2020;80(6): e14-e18.
- 331 doi:10.1016/j.jinf.2020.03.005
- 332 11. Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe
- 333 COVID-19 and establishment of a host risk score: findings of 487 cases outside
- 334 Wuhan. Crit Care. 2020;24(1):108. doi:10.1186/s13054-020-2833-7.
- 335 12. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, Cuomo-
- 336 Dannenburg G, Thompson H, Walker PGT, Fu H, Dighe A, Griffin JT, Baguelin
- 337 M, Bhatia S, Boonyasiri A, Cori A, Cucunubá Z, FitzJohn R, Gaythorpe K, Green
- 338 W, Hamlet A, Hinsley W, Laydon D, Nedjati-Gilani G, Riley S, van Elsland S,
- 339 Volz E, Wang H, Wang Y, Xi X, Donnelly CA, Ghani AC, Ferguson NM.
- 340 Estimates of the severity of coronavirus disease 2019: a model-based analysis. The
- 341
 Lancet Infectious Diseases. 2020;30:S1473-3099(20)30243-7. doi:10.1016/S1473
- 342 3099(20)30243-7
- 343 13. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan
- 344 L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and
- risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a

346 retrospective cohort study. Lancet. 2020;395(10229):1054-1062.

347 doi:10.1016/S0140-6736(20)30566-3.

348 14. Baas T, Roberts A, Teal TH, Vogel L, Chen J, Tumpey TM, Katze MG, Subbarao

349 K. Genomic analysis reveals age-dependent innate immune responses to severe

- acute respiratory syndrome coronavirus. J Virol. 2008;82(19):9465-76. doi:
- 351 10.1128/JVI.00489-08
- 352 15. Chen J, Lau YF, Lamirande EW, Paddock CD, Bartlett JH, Zaki SR, Subbarao K.
- 353 Cellular immune responses to severe acute respiratory syndrome coronavirus

- 355 control of SARS-CoV infection. J Virol. 2010;84(3):1289-301.
- 356 doi:10.1128/JVI.01281-09
- 357 16. Roberts A, Paddock C, Vogel L, Butler E, Zaki S, Subbarao K. Aged BALB/c mice
- as a model for increased severity of severe acute respiratory syndrome in elderly
- 359 humans. J Virol. 2005;79(9):5833-8. doi:10.1128/JVI.79.9.5833-5838.2005
- 360 17. Arabi YM, Hajeer AH, Luke T, Raviprakash K, Balkhy H, Johani S, Al-Dawood A,
- 361 Al-Qahtani S, Al-Omari A, Al-Hameed F, Hayden FG, Fowler R, Bouchama A,
- 362 Shindo N, Al-Khairy K, Carson G, Taha Y, Sadat M, Alahmadi M. Feasibility of
- 363 Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi
- 364 Arabia. Emerg Infect Dis. 2016;22(9):1554-61. doi:10.3201/eid2209
- 365 18. Drosten C, Meyer B, Müller MA, Corman VM, Al-Masri M, Hossain R, Madani H,
- 366 Sieberg A, Bosch BJ, Lattwein E, Alhakeem RF, Assiri AM, Hajomar W, Albarrak
- 367 AM, Al-Tawfiq JA, Zumla AI, Memish ZA. Transmission of MERS-coronavirus in
- 368 household contacts. N Engl J Med. 2014;371(9):828-35.
- 369 doi:10.1056/NEJMoa1405858
- 370 19. Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19:
- immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363-374.
- 372 doi:10.1038/s41577-020-0311-8
- 373 20. Tetro JA. Is COVID-19 receiving ADE from other coronaviruses? Microbes Infect.
 374 2020;22(2):72-73. doi:10.1016/j.micinf.2020.02.006
- 375 21. Wan Y, Shang J, Sun S, Tai W, Chen J, Geng Q, He L, Chen Y, Wu J, Shi Z, Zhou
- 376 Y, Du L, Li F. Molecular Mechanism for Antibody-Dependent Enhancement of
- 377 Coronavirus Entry. J Virol. 2020;94(5):e02015-19. doi:10.1128/JVI.02015-19.
- 378 22. Yang ZY, Werner HC, Kong WP, Leung K, Traggiai E, Lanzavecchia A, Nabel GJ.
- 379 Evasion of antibody neutralization in emerging severe acute respiratory syndrome

380 coronaviruses. Proc Natl Acad Sci. 2005;102(3):797-801.

- 381 doi:10.1073/pnas.0409065102
- 382 23. Ministry of Health, Labour and Welfare, Japan. Documents for press release. –
- 383 Available at <u>https://www.mhlw.go.jp/content/10906000/000628510.pdf</u>. (In
- 384 Japanese, accessed on 13th May 2020)
- 38524. EpiCentro, Istituto Superiore di Sanità. Infographic available in English 13 may
- 2020 update in COVID-19 integrated surveillance: key national data. Available at
 https://www.epicentro.iss.it/en/coronavirus/sars-cov-2-integrated-surveillance-data.
- 388 (Accessed on 13th May 2020)
- 25. Centro de Coordinación de Alertas y Emergencias Sanitarias. Actualización nº 103.
 Enfermedad por el coronavirus (COVID-19). 12.05.2020. Available at
- 391 https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-
- 392 <u>China/documentos/Actualizacion_103_COVID-19.pdf</u>. (In Spanish, accessed 13th
 393 May 2020)
- 26. Zhuang Z, Zhao S, Lin Q, Cao P, Lou Y, Yang L, Yang S, He D, Xiao L.
- 395 Preliminary estimates of the reproduction number of the coronavirus disease
- 396 (COVID-19) outbreak in Republic of Korea and Italy by 5 March 2020. Int J Infect
 397 Dis. 2020;95:308-310. doi:10.1016/j.ijid.2020.04.044
- 398 27. D'Arienzo M, Coniglio A. Assessment of the SARS-CoV-2 basic reproduction
- number, R0, based on the early phase of COVID-19 outbreak in Italy. Biosafety
- 400 and Health. 2020;In Press. doi:10.1016/j.bsheal.2020.03.004
- 401 28. Expert Meeting on the Novel Coronavirus Disease Control. The minutes of the fifth
 402 meeting. 2020 March 2. Available at:
- 403 <u>https://www.kantei.go.jp/jp/singi/novel_coronavirus/senmonkakaigi/sidai_r020302.</u>
 404 pdf. (In Japanese, accessed 13th May 2020)
- 404 $\underline{pdl.}$ (in Japanese, accessed 13th May 2020)
- 29. Caicedo-Ochoa Y, Rebellón-Sánchez DE, Peñaloza-Rallón M, Cortés-Motta HF,
 Méndez-Fandiño YR. Effective Reproductive Number Estimation for Initial Stage
- 407 of COVID-19 Pandemic in Latin American Countries. Int J infect Dis.
- 408 2020;95:316-318. doi:10.1016/j.ijid.2020.04.069
- 30. Gostic K, Gomez ACR, Kucharski AJ, Lloyd-Smith JO. Effectiveness of traveller
 screening for emerging pathogens is shaped by epidemiology and natural history of
 infection. Elife. 2020; 2015;4: e05564. doi: 10.7554/eLife.05564
- 412 31. Gostic K, Gomez ACR, Mummah RO, Kucharski AJ, Lloyd-Smith JO. Estimated
- 413 effectiveness of symptom and risk screening to prevent the spread of COVID-19.
- 414 Elife. 2020; 9. doi: 10.7554/eLife.55570

415 32. Omori R, Mizumoto K, Chowell G. Changes in testing rates could mask the novel coronavirus disease (COVID-19) growth rate. Int J Infect Dis. 2020;94:116-118. 416 417 doi:10.1016/j.ijid.2020.04.021 418 33. Tsang TK, Wu P, Lin Y, Lau EH, Leung GM, Cowling BJ. Effect of changing case 419 definitions for COVID-19 on the epidemic curve and transmission parameters in 420 mainland China: a modelling study. Lancet Public Health. 2020; 5; 5; e289-e296. 421 doi:10.1016/S2468-2667(20)30089-X. 422 34. Bar-on YM, Flamholz A, Phillips R, and Milo R. SARSCoV-2 (COVID-19) by the 423 numbers. Elife. 2020;9:e57309. doi:10.7554/eLife.57309 424 35. Linton NM, Kobayashi T, Yang Y, Hayashi K, Akhmetzhanov AR, Jung SM, Yuan 425 B, Kinoshita R, Nishiura H. Incubation Period and Other Epidemiological 426 Characteristics of 2019 Novel Coronavirus Infections with Right Truncation: A 427 Statistical Analysis of Publicly Available Case Data. J Clin Med. 2020;9(2):538. 428 doi:10.3390/jcm9020538 429 36. Shim E, Tariq A, Choi W, Lee Y, Chowell G. Transmission potential and severity 430 of COVID-19 in South Korea. Int J Infect Dis. 2020;93:339-344. doi: 431 10.1016/j.ijid.2020.03.031 432 37. Sun K, Chen J, Viboud C. Early epidemiological analysis of the coronavirus 433 disease 2019 outbreak based on crowdsourced data: a population-level 434 observational study. Lancet Digital Health. 2020;2:e201-e208. doi:10.1016/S2589-435 7500(20)30026-1 436 38. Ghani AC, Donnelly CA, Cox DR, Griffin JT, Fraser C, Lam TH, Ho LM, Chan 437 WS, Anderson RM, Hedley AJ, Leung GM. Methods for estimating the case fatality ratio for a novel, emerging infectious disease. Am J Epidemiol. 438 439 2005;162:479-486. doi:10.1093/aje/kwi230 440 39. Garske T, Legrand J, Donnelly CA, Ward H, Cauchemez S, Fraser C, Ferguson 441 NM, Ghani AC. Assessing the severity of the novel influenza A/H1N1 pandemic. 442 BMJ. 2008:339;b2840. doi: 10.1136/bmj.b2840 443 40. Woodall H, Adams B. Partial cross-enhancement in models for dengue 444 epidemiology. J Theor Biol. 2014;351:67-73. doi: 10.1016/j.jtbi.2014.02.016 445 41. Recker M, Blyuss KB, Simmons CP, Hien TT, Wills B, Farrar J, Gupta S. 446 Immunological serotype interactions and their effect on the epidemiological pattern 447 of dengue. Proc Biol Sci. 2009 Jul 22;276(1667):2541-8. doi:

448 10.1098/rspb.2009.0331. Epub 2009 Apr 15. PMID: 19369266; PMCID:

449 PMC2684681.

450 42. Tang B, Huo X, Xiao Y, Ruan S, Wu J. A conceptual model for optimizing vaccine
451 coverage to reduce vector-borne infections in the presence of antibody-dependent
452 enhancement. Theor Biol Med Model. 2018;15(1):13. doi:10.1186/s12976-018-

- 453 0085-x
- 454 43. Ferguson N, Anderson R, Gupta S. The effect of antibody-dependent enhancement
 455 on the transmission dynamics and persistence of multiple-strain pathogens. Proc
 456 Natl Acad Sci. 1999;96(2):790-4. doi:10.1073/pnas.96.2.790.

457 44. Ferguson N, Andreasen V. The influence of different forms of cross-protective

- 458 immunity on the population dynamics of antigenetically diverse populations.
- 459 Castillo-Chavez C, Blower S, Kirschner D, van den Driessche P, Yakubu A (Eds.),

460 Mathematical Approaches for Emerging and Reemerging Infectious Diseases:

461 Models, Methods and Theory. IMA Volumes Mathematics and its Applications,

462 vol. 126, Kluwer Academic Publishers, New York. 2002;157-169.

- 463 45. Kawaguchi I, Sasaki A, Boots M. Why are dengue virus serotypes so distantly
 464 related? Enhancement and limiting serotype similarity between dengue virus
 465 strains. Proc Biol Sci. 2003;270(1530):2241-7. doi:10.1098/rspb.2003.2440
- 466 46. Prem K, Liu Y, Russell TW, Kucharski AJ, Eggo RM, Davies N. The effect of
 467 control strategies to reduce social mixing on outcomes of the COVID-19 epidemic
 468 in Wuhan, China: a modelling study. Lancet Public Health. 2020;e261-e270.
- 469 doi:10.1016/S2468-2667(20)30073-6
- 470 47. Prem K, Cook AR, Jit M. Projecting social contact matrices in 152 countries using
 471 contact surveys and demographic data. PLoS Comput Biol. 2017;13(9):e1005697.
 472 doi:10.1371/journal.pcbi.1005697
- 473 48. Diekmann O, Heesterbeek JAP. Mathematical epidemiology of infectious diseases.
 474 Model building, analysis and interpretation. 2000;Chichester (UK):Wiley.
- 475 49. Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, et al. Social
- 476 Contacts and Mixing Patterns Relevant to the Spread of Infectious Diseases. PLoS
 477 Med. 2008;5(3):e74. doi:10.1371/journal.pmed.0050074
- 478 50. United Nations, 2020. Annual Population Indicators in Standard Projections.
- 479 Available at <u>https://population.un.org/wpp/Download/Standard/Interpolated/</u>.
- 480 (Accessed 13th May 2020)

481

482

483 Figures

484

- 485 Figure 1: The age distribution of mortality by COVID-19 in Italy reported on 13th May
- 486 2020, Japan reported on 7th May 2020, and Spain reported on 12th May 2020. Circle,





- 491 Figure 2: The sensitivity of (a) age-dependency of susceptibility and (b) transmission
- 492 coefficient β against age distribution of mortality when age-independent mortality was
- 493 assumed. In panel (a), all parameters except the exponent parameter φ , describing the
- 494 variation of susceptibility among age groups, were fixed and parameterized as $R_0 = 2.9$
- 495 in the setting for Spain. In panel (b), all parameters parameterized as the setting for

496 Spain (ϕ =12.3) except were fixed except transmission coefficient β . (a) Sensitivity of age-specific susceptibility against (b) Sensitivity of transmission coefficient β against age distribution of deaths age distribution of deaths 1.0 1.0 Exponent parameter φ R 0.8 2.3 0.8 1.5 7.3 2.0 12.3 Proportion 2.5 Proportion 0.6 0.6 17.3 3.0 22.3 3.5 0.4 0.4 0.2 0.2 10-19 20-29 30-39 <10 40-49 50-59 60-69 70 +<10 10-19 20-29 30-39 40-49 50-59 60-69 497 Age Age 498

70 +

- 499 Figure 3: The sensitivity of transmission coefficient β against age distribution of
- 500 mortality when it was assumed that age-dependent mortality was proportional to cCFR
- 501 per age group. All parameters were fixed and parameterized as the setting for Spain
- 502 except the transmission coefficient β .



- 505 Figure 4: The estimate of exponent parameter φ describing the variation of
- 506 susceptibility among age groups assuming that mortality rate does not depend on age.
- 507 True and broken lines represent the maximum likelihood estimates and 95% confidence
- 508 intervals, respectively.

509

510 511



- 512 Figure 5: The estimate of exponent parameter φ describing the variation of
- susceptibility among age groups assuming that mortality rate does not depend on age 513
- and the fraction of infections that becomes symptomatic among all COVID-19 cases is 514
- 515 0.25. True and broken lines represent the maximum likelihood estimates and 95%
- 516 confidence intervals, respectively.



519

517

- 520 Figure 6: The estimate of exponent parameter φ describing the variation of
- 521 susceptibility among age groups assuming that mortality rate does not depend on age
- and the fraction of infections that becomes symptomatic among all COVID-19 cases is
- 523 0.5. True and broken lines represent the maximum likelihood estimates and 95%
- 524 confidence intervals, respectively.





- 528 Figure 7: The estimate of exponent parameter φ describing the variation of
- 529 susceptibility among age groups assuming that mortality rate does not depend on age
- and the fraction of infections that becomes symptomatic among all COVID-19 cases is
- 531 0.05. True and broken lines represent the maximum likelihood estimates and 95%
- 532 confidence intervals, respectively.

